Paul Miranda, MD

Board-Certified in Family Medicine · Emergency Physician · Obesity Medicine Association member

I’m an emergency and Family Medicine physician in Chattanooga, Tennessee, and founder of Summit Metabolic Health. I read every patient chart personally. This article reports on a topic patients keep asking about — it is education, not an endorsement.

Medically reviewed by Paul Miranda, MD

If you’re in Chattanooga and you’ve looked up Mochi Health, you’re probably comparing it to something local — maybe to Summit. That’s a fair comparison to want to make, and I’d want to make it too if I were sitting where you’re sitting: tired of waiting rooms, tired of “starting at” prices that turn into something else at checkout, wondering if an app can just handle this for you. I’m Dr. Paul Miranda. I’m a board-certified family medicine physician, I work ER shifts here in Chattanooga, and I built Summit Metabolic Health as 100% telehealth — so this isn’t a pitch for walking into an office instead of using your phone. It’s a question about who’s actually reading your chart when the dose needs to change.

Nobody searches “Mochi Health alternative” because they hate their phone. They search it because something didn’t add up — the price crept past what the homepage promised, a dose change got approved by a message thread instead of a conversation, or they just want to know if there’s a real doctor on the other end before they put a GLP-1 in their body for the next year. That instinct is correct. App-based GLP-1 care solved a real problem: it got rid of the three-week wait for an appointment and the conversation some people would rather not have in person. I’m not going to pretend convenience doesn’t matter — it does, and Mochi deserves credit for making GLP-1 access faster than it used to be. The honest question isn’t whether telehealth works. It’s what kind of telehealth you’re getting underneath the app.

Here’s the part most comparison posts skip: not all telehealth is built the same way. Some platforms route your intake through a form, an algorithm scores it, and a clinician signs off in batches — reviewing volume, not depth. At Summit, I personally review every chart myself before a prescription goes out and before any dose changes. Not a nurse queue. Not a script a computer picked for you.

That distinction got real scrutiny in October 2026, when Hims & Hers — the largest name in this category — was hit with a securities-fraud lawsuit alleging the company misled investors about exactly this kind of oversight gap. I’m not naming that to pile on a competitor. I’m naming it because it’s the clearest public evidence yet that “who’s actually reviewing this” isn’t a marketing detail. It’s the whole model.

Mochi, like most app-based GLP-1 subscriptions, is built to move volume through a protocol efficiently. That’s not an insult — it’s the business model, and it’s why they can be fast. It’s also why an NP-led or algorithm-driven chart review is structured to advance you through a standard pathway, not to stop, look at your specific tolerance and labs, and make a judgment call that departs from the standard pathway when your case calls for it.

None of that means the people answering your messages on an app platform are careless. It means the system around them is built for throughput. A chart review that has minutes to spend per patient, across thousands of patients, has to default to the standard step. A chart review built around a smaller patient panel, run by the physician whose name is on the prescription, has room to do something different when something different is what your chart actually shows.

Here’s where I’ll be blunt, because nobody else is. After the compounding exodus that followed the February 2026 FDA shortage resolution, most direct-to-consumer telehealth platforms shifted patients onto brand-name drug at brand-name pricing once their introductory compounded rate expired. That’s landed most platforms at $448 to $548 a month once the honeymoon pricing runs out. At Summit, flat compounded pricing runs $249 to $449 — covering the visit, the chart review, and every dose adjustment, not just the vial. I’d rather you hear that gap from me now than find it on a credit card statement in month four.

This is the clinical heart of the comparison, and it’s the part an app can’t fake. STEP 1 (Wilding et al., NEJM, 2021) and SURMOUNT-1 (Jastreboff et al., NEJM, 2022) both built their dose-escalation steps around how a patient actually tolerated each one — nausea, GI symptoms, how fast someone could reasonably move to the next dose — not a fixed calendar everyone follows identically. SELECT (Lincoff et al., NEJM, 2023) added another layer: it showed cardiovascular benefit from semaglutide independent of diabetes status, which means a dosing decision has to weigh more than the number on the scale. A patient chasing weight-loss percentage and a patient carrying cardiovascular risk may need a different pace on the same drug.

That’s a judgment call. A protocol — the kind an algorithm runs or a high-volume NP queue defaults to — is built to move you through fixed steps, not to stop and ask whether this particular week calls for holding the dose instead of raising it. I slow-walk dose escalation on purpose, hold doses when a patient needs it, and plan the taper down at goal weight the same way I plan the climb up. That’s not extra service. That’s the medicine.

Summit is telehealth — I’m not asking you to drive anywhere or sit in a waiting room. But the physician running your care lives in this city, works ER shifts at the hospital down the road, and reads your chart personally, the same way I’d want my own family’s chart read. Mochi, and most national platforms like it, operate at a scale where that kind of continuity isn’t the design goal — speed and volume are. If something about your case doesn’t fit the standard pathway, you want the person reviewing it to be reachable, not a queue.

If Mochi has worked for you — nothing bothering you along the way, steady progress, no surprise pricing — there’s no reason to switch something that isn’t broken. But if you’re paying more than you expected, moving through doses faster than your body is telling you is comfortable, or you’ve never actually had a conversation with the physician attached to your prescription, that’s worth a second look.

I’ve written more on what to actually check before picking any GLP-1 provider, Mochi included, in what to look for in a GLP-1 provider in Chattanooga, and I go deeper on how dose titration itself decides who actually tolerates treatment in semaglutide side effects and why dosing pace matters. If you’ve already run this exact comparison against a different telehealth brand, the reasoning holds up the same way in Henry Meds vs. a local weight loss clinic — the questions to ask don’t change by brand name. The full list of pieces like this lives on the Summit Metabolic Health blog.

Ready to start? Apply at summitmetabolichealth.com/apply.

This post is educational and does not replace individualized medical advice. Talk with a licensed physician about your own history before starting or changing any medication.